RA Capital Management’s C4 Therapeutics CCCC Stock Holding History

RA Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.4M	Hold	8,000,000	–	–	0.32%	46
2026 Q1	$21M	Hold	8,000,000	–	–	0.22%	57
2025 Q4	$15.3M	Buy	+8,000,000	New	+$19M	0.16%	54
2025 Q1	–	Sell	-4,878,000	Closed	-$17.6M	–	89
2024 Q4	$17.6M	Hold	4,878,000	–	–	0.23%	61
2024 Q3	$27.8M	Hold	4,878,000	–	–	0.32%	49
2024 Q2	$22.5M	Hold	4,878,000	–	–	0.3%	51
2024 Q1	$39.9M	Hold	4,878,000	–	–	0.51%	45
2023 Q4	$27.6M	Buy	+4,878,000	New	+$11.1M	0.43%	41
2022 Q1	–	Sell	-1,377,569	Closed	-$44.4M	–	98
2021 Q4	$44.4M	Hold	1,377,569	–	–	0.78%	38
2021 Q3	$61.5M	Hold	1,377,569	–	–	0.85%	35
2021 Q2	$52.1M	Hold	1,377,569	–	–	0.84%	39
2021 Q1	$51M	Hold	1,377,569	–	–	0.77%	39
2020 Q4	$45.6M	Buy	+1,377,569	New	+$39.9M	0.64%	42

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

RA Capital Management's CCCC Position: Q2 2026 in Review

RA Capital Management held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 8,000,000 shares worth $37.4M. The position accounts for 0.32% of the portfolio, ranked #46.

RA Capital Management first reported a position in CCCC in Q4 2020 and has held it in 13 quarters since. The position peaked at $61.5M in Q3 2021. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

RA Capital Management held 8,000,000 shares of C4 Therapeutics worth $37.4M as of Q2 2026.
RA Capital Management left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up 0.32% of RA Capital Management's portfolio in Q2 2026, its #46 holding.
RA Capital Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 13 quarters since.
RA Capital Management's C4 Therapeutics position peaked at $61.5M in Q3 2021.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.